Mesoblast (MESO) Non-Current Receivables (2015 - 2025)
Mesoblast recorded quarterly Non-Current Receivables of $43.3 million in Q4 2025, up 106.66% quarter-over-quarter from $21.0 million in Q4 2024, and up 106.66% year-over-year from $21.0 million in Q4 2024.
Mesoblast's Non-Current Receivables history runs 7 years deep, the most recent figure standing at $43.3 million for Q4 2025.
- In Q4 2025, Non-Current Receivables rose 106.66% year-over-year to $43.3 million; the TTM figure through Dec 2025 stood at $43.3 million (up 106.66% YoY), while the FY2018 annual figure was $50.4 million, up 1245.61% from the prior year.
- Non-Current Receivables came in at $43.3 million for Q4 2025 at Mesoblast, up from $21.0 million in the prior quarter.
- In the past five years, Non-Current Receivables ranged from a high of $43.3 million in Q4 2025 to a low of $4.4 million in Q4 2022.
- A 4-year average of $16.0 million and a median of $7.0 million in 2023 frame the typical range for Non-Current Receivables.
- Across the five-year window, Non-Current Receivables jumped 58.94% in 2023 and soared 199.4% in 2024, its largest moves.
- Mesoblast's Non-Current Receivables stood at $4.4 million in 2022, then surged by 58.94% to $7.0 million in 2023, then jumped by 199.4% to $21.0 million in 2024, then soared by 106.66% to $43.3 million in 2025.
- According to Business Quant data, Non-Current Receivables over the past three periods registered $43.3 million, $21.0 million, and $7.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 4.49 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Mesoblast | 23.40 Bn | 23.27 Bn | - | 43.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 43.30 Mn |
| Dec 31, 2024 | 20.95 Mn |
| Dec 31, 2023 | 7.00 Mn |
| Mar 31, 2023 | 4.40 Mn |
| Dec 31, 2022 | 4.40 Mn |
| Sep 30, 2018 | 29.54 Mn |
| Jun 30, 2018 | 50.37 Mn |
| Mar 31, 2018 | 12.07 Mn |
| Dec 31, 2017 | 12.24 Mn |
| Sep 30, 2017 | 4.59 Mn |
| Jun 30, 2017 | 3.74 Mn |
| Dec 31, 2015 | 7.83 Mn |
| Jun 30, 2015 | 3.97 Mn |